

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT
FELDMAN ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/M.F./	AA	2003/0114389A1	6/19/03	Webb	514	19	
/M.F./	AB	2003/229007	12/11/03	Levi et al.	514	2	
/M.F./	AC	4,885,292	12/5/89	Ryono et al.	514	211	
/M.F./	AD	5,376,638	12/27/94	Young et al.	514	12	
/M.F./	AE	5,182,266	1/26/93	Kleinert	514	18	
/M.F./	AF	5,202,322	4/13/93	Allen et al.	514	228.2	
/M.F./	AG	5,821,232	10/13/98	Fossa	514	18	
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI	0-548-076-A2	12/10/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	0-573-652-A1	9/17/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AK	EP-4-042-370-A1	5/24/93	EP			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AL	Alilikrete, "Alilikrete Speedel" Current Opinion in Investigational Drugs, Vol. 8, No. 10, pp 1473-1482, (2002)
	AM	Azizi et al. "Pharmacologic Demonstration of the Synergistic Effects of combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II Renin Feedback Interruption." J. Am. Soc. Nephrol. 15, pp 3126-3133 (2004).
	AN	Bears et al. The Merck Manual of diagnosis and Therapy, Seventeenth Edition, XP002364176 (1999)
	AO	Boyer et al., "Dose-dependent effects on blood pressure and the rennin-angiotensin system with a new orally active rennin inhibitor." Clinical Pharmacology and Therapeutics, vol. 53, no. 2, p 140 (1993)
	AP	Fossa et al. "Synergistic Effect on Reduction in Blood Pressure With coadministration of a Renin Inhibitor or an Angiotensin Converting Enzyme Inhibitor With an Angiotensin II Receptor Antagonist" Drug Development Research 33, pp 422-426 (1994)
	AQ	Himmelmenn et al. "Remikiren (Ro-42-5892) - An Orally Active Renin Inhibitor in Essential Hypertension" AJH, Vol. 8, No. 6, pp 517-522 (1996)
	AR	Malbaum et al. "Renin inhibitors as novel treatments for cardiovascular disease" Monthly Focus: Cardiovascular, Renal, Endocrine & Metabolic, Expert Opinion Ther. Patents No. 13(5), pp 589-603 (2002)

EXAMINER

/Meghan Finn/

DATE CONSIDERED

05/29/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33687-US-PCT
APPLICATION NO.APPLICANT
FELDMAN ET AL.
FILING DATE

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA	WO 01/15673 A2	3/8/01	WO				
	BB	WO 01/15674 A	3/8/01	WO				
	BC	WO 03/035640A2	5/1/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BD	WO 03/007008A1	11/27/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BE	WO 03/000270A1	12/4/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BF	WO 03/000767A1	12/4/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BG	WO 02/10097	6/25/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BH	WO2004/002549A1	1/8/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BI	WO2004/002957A1	1/8/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BJ	WO2004/100871A2	11/25/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BK	WO 02/40007 A1	5/23/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BL	WO2005/023109A2	3/17/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BM	WO2005/054244A2	6/16/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO2005/070486	8/4/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO2005/077410A1	8/25/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>
	BR						<input type="checkbox"/>	<input type="checkbox"/>
	BS						<input type="checkbox"/>	<input type="checkbox"/>
	BT						<input type="checkbox"/>	<input type="checkbox"/>
	BU						<input type="checkbox"/>	<input type="checkbox"/>
	BV						<input type="checkbox"/>	<input type="checkbox"/>
	BW						<input type="checkbox"/>	<input type="checkbox"/>
	BX						<input type="checkbox"/>	<input type="checkbox"/>
	BY						<input type="checkbox"/>	<input type="checkbox"/>
	BZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

/Meghan Finn/

DATE CONSIDERED

05/29/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.